Abstract
The rapid increase of health-threatening infections by Gram-negative pathogens along with the emergence of multidrugresistant bacterial strains demands the development of novel antibiotics directed against the previously unexploited targets. One of the promising targets in Gram-negative bacteria is the zinc-dependent metalloamidase, UDP-3-O-(R-3-hydroxymyristoyl)-Nacetylglucosamine deacetylase (LpxC). LpxC catalyzes the first committed, second overall step in the biosynthetic pathway of lipid A. Thus, research on LpxC inhibitors as antibacterial agents has become an attractive field in the development of the novel antibiotic therapy of Gram-negative bacteria. In this review, we will summarize the recent progress in the studies on the structure, catalytic mechanism and regulation of LpxC and the current development of LpxC inhibitors.
Keywords: Gram-negative bacteria, MDR, lipid A, biosynthesis, LpxC, Structure, FtsH, LpxC Inhibitors
Current Medicinal Chemistry
Title:UDP-3-O-(R-3-hydroxymyristoyl)-N-Acetylglucosamine Deacetylase (LpxC) Inhibitors: A New Class of Antibacterial Agents
Volume: 19 Issue: 13
Author(s): J. Zhang, L. Zhang, X. Li and W. Xu
Affiliation:
Keywords: Gram-negative bacteria, MDR, lipid A, biosynthesis, LpxC, Structure, FtsH, LpxC Inhibitors
Abstract: The rapid increase of health-threatening infections by Gram-negative pathogens along with the emergence of multidrugresistant bacterial strains demands the development of novel antibiotics directed against the previously unexploited targets. One of the promising targets in Gram-negative bacteria is the zinc-dependent metalloamidase, UDP-3-O-(R-3-hydroxymyristoyl)-Nacetylglucosamine deacetylase (LpxC). LpxC catalyzes the first committed, second overall step in the biosynthetic pathway of lipid A. Thus, research on LpxC inhibitors as antibacterial agents has become an attractive field in the development of the novel antibiotic therapy of Gram-negative bacteria. In this review, we will summarize the recent progress in the studies on the structure, catalytic mechanism and regulation of LpxC and the current development of LpxC inhibitors.
Export Options
About this article
Cite this article as:
Zhang J., Zhang L., Li X. and Xu W., UDP-3-O-(R-3-hydroxymyristoyl)-N-Acetylglucosamine Deacetylase (LpxC) Inhibitors: A New Class of Antibacterial Agents, Current Medicinal Chemistry 2012; 19 (13) . https://dx.doi.org/10.2174/092986712800167374
DOI https://dx.doi.org/10.2174/092986712800167374 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Minoxidil Use in Dermatology, Side Effects and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery The Effects of Obesity on the Cerebral Vasculature
Current Vascular Pharmacology Curcumin has Bright Prospects for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design The Complement Cascade: New Avenues in Stroke Therapy
Current Vascular Pharmacology DBU-Catalyzed One-Pot Multicomponent Reaction for the Synthesis of Spirocyclic Tetrahydrothiophene Derivatives
Current Organocatalysis Recognition of Peptides by Antibodies and Investigations of Affinity Using Biosensor Technology
Combinatorial Chemistry & High Throughput Screening Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme
Current Medicinal Chemistry Different Methods for Cell Viability and Proliferation Assay: Essential Tools in Pharmaceutical Studies
Anti-Cancer Agents in Medicinal Chemistry Implications of the Molecular Basis of Prostacyclin Biosynthesis and Signaling in Pharmaceutical Designs
Current Pharmaceutical Design Is the Vascular System a Main Target for Thyroid Hormones? From Molecular and Biochemical Findings to Clinical Perspectives
Current Vascular Pharmacology Recent Advances in Treatment Approaches to Gaucher Disease
Current Pharmaceutical Biotechnology Evaluating the Effects of Oral and Topical Simvastatin in the Treatment of Acne Vulgaris: A Double-blind, Randomized, Placebo-controlled Clinical Trial
Current Clinical Pharmacology Novel Aceclofenac-L-Cystine and Aceclofenac-Urea Cocrystals with Enhanced Oral Bioavailability
Current Drug Delivery Patent Selections
Recent Patents on Biotechnology Kernel-Based Feature Selection Techniques for Transport Proteins Based on Star Graph Topological Indices
Current Topics in Medicinal Chemistry Wide-Ranging Genomic Effects of Plasticisers and Related Compounds
Current Drug Metabolism Computational Analysis of the Binding Site(s) of TNF β-TNFR1 Complex: Implications for Designing Novel Anticancer Agents
Clinical Cancer Drugs Biological Properties of Plant-Derived Alkylresorcinols: Mini-Review
Mini-Reviews in Medicinal Chemistry The Cancer Hygiene Hypothesis: From Theory to Therapeutic Helminths
Current Cancer Therapy Reviews Ginsenoside Rb1 Directly Scavenges Hydroxyl Radical and Hypochlorous Acid
Current Pharmaceutical Design